Renal biomarkers are anticipated to reach US$ 2.6 billion in global demand by 2032, growing at a 7.0% annual rate year over year.
Because kidney problems are becoming more common and there is a growing need for early and precise detection, the renal biomarker market has grown significantly in recent years. Renal biomarkers are particular indicators found in bodily fluids such as blood, urine, or other tissues that can offer important information about kidney function and identify early indicators of renal injury or malfunction.
The rising prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD) is one of the main factors driving the market’s growth. Millions of people worldwide suffer from chronic kidney disease (CKD), and preventing the illness’s progression and improving patient outcomes depend on early kidney dysfunction detection. Renal biomarkers are essential for early detection of kidney disease.
Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-1731
Global demand for renal biomarkers is expected to rise 7.0% year on year to US$ 2.6 billion by 2032, driven by:
- Global increases in kidney disease incidence
- a sizable geriatric population, particularly in developing countries
- The prevalence of multiple co-morbidities is increasing.
- Diabetes, obesity, and hypertension are all becoming more common.
- an increase in the world’s vulnerable ageing population
Moreover, the aging population and the rise in risk factors such as diabetes, hypertension, and obesity have contributed to the growing prevalence of kidney disorders. As the elderly population increases, the demand for renal biomarkers for timely diagnosis and management of kidney diseases is expected to rise.
The market offers a variety of renal biomarker tests, including serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (UACR), among others. These biomarkers help healthcare professionals assess kidney function, identify the presence of proteinuria (a marker of kidney damage), and monitor disease progression.
Competitive Landscape
Key market players within the renal biomarker market are concentrating on new product launches and approvals, investments in research and development, partnerships, acquisitions, and collaborations to gain a competitive edge in the market.
Elevate Strategy: Tap into Analyst Expertise Now :
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1731
Key instances of development within the market include:
- SphingoTec GmbH reported the publication of unique study findings including their patented pencil kidney function biomarker in BMC Emergency Medicine in December 2019.
- In order to include novel kidney disease biomarkers found by the center’s researchers in Renalytix AI’s KidneyIntelX platform, the business expanded its collaboration with the Joslin Diabetes Center in April 2021.
Key Companies Profiled :
- Abbott Laboratories
- BioPorto Diagnostics AS
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Nexelis (Pacific Biomarkers)
- BioMérieux
- Sphingotec GmbH
- Randox Laboratories Ltd
- Siemens Healthineers AG
- Beckman Coulter Inc. (Danaher Corporation)
- Bio-Rad Laboratories Inc.
- Enzo Biochem Inc.
- PerkinElmer Inc.
- Renalytix AI
Key Segments :
By Biomarker:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-Regulated Proteins
- Neutrophil Gelatinase-Associated Lipocalin
- Kidney Injury Molecule-1
- Interleukin-18
- Others
By Diagnostic Technique:
- Enzyme Linked Immunosorbent Assay (ELISA)
- Particle-Enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography-Mass Spectrometry (LS-MS)
By End User:
- Diagnostic Labs
- Outpatient Clinics
- Research Centers
- Hospitals
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Unleash Potential: Craft Your Customized Report Now :
https://www.futuremarketinsights.com/customization-available/rep-gb-1731
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube